Nautilus Gross Profit from 2010 to 2024

NAUT Stock

USD 2.40 0.02 0.84%

Nautilus Biotechnology Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit will likely drop to about -6 M in 2024. Gross Profit is the profit Nautilus Biotechnology makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-5.7 M

Current Value

-6 M

Quarterly Volatility

1.2 M

Credit Downgrade

Yuan Drop

Covid

Check Nautilus Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nautilus Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 7 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.12. Nautilus financial statements analysis is a perfect complement when working with Nautilus Biotechnology Valuation or Volatility modules.

Check out the analysis of Nautilus Biotechnology Correlation against competitors.

For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.

Latest Nautilus Biotechnology's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Nautilus Biotechnology over the last few years. Gross profit is a required income statement account that reflects total revenue of Nautilus Biotechnology minus its cost of goods sold. It is profit before Nautilus Biotechnology operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Nautilus Biotechnology's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nautilus Biotechnology's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Nautilus Gross Profit Regression Statistics

	Arithmetic Mean	(2,917,283)
	Coefficient Of Variation	(42.04)
	Mean Deviation	847,920
	Median	(2,346,000)
	Standard Deviation	1,226,461
	Sample Variance	1.5T
	Range	3.6M
	R-Value	(0.69)
	Mean Square Error	848.3B
	R-Squared	0.48
	Significance	0
	Slope	(189,278)
	Total Sum of Squares	21.1T

Nautilus Gross Profit History

	2024	-6 M
	2023	-5.7 M
	2022	-3.4 M
	2021	-2.8 M

Other Fundumenentals of Nautilus Biotechnology

Gross Profit Margin

Nautilus Biotechnology Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Accounts Payable	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt
Total Assets		0.94	-0.71	-0.7	-0.44	-0.45	0.87	0.89	0.87	0.89	0.35	-0.19	0.9	-0.31	0.92	0.9	0.87	0.61
Total Stockholder Equity	0.94		-0.46	-0.8	-0.69	-0.73	0.94	0.98	0.94	0.96	0.44	-0.25	0.97	-0.37	0.98	0.97	0.91	0.68
Net Debt	-0.71	-0.46		0.2	-0.01	-0.19	-0.52	-0.4	-0.39	-0.45	-0.29	-0.14	-0.41	-0.05	-0.47	-0.41	-0.52	-0.11
Retained Earnings	-0.7	-0.8	0.2		0.76	0.71	-0.73	-0.88	-0.93	-0.88	-0.67	0.68	-0.91	0.79	-0.86	-0.92	-0.68	-0.92
Short Term Investments	-0.44	-0.69	-0.01	0.76		0.91	-0.76	-0.76	-0.73	-0.75	-0.77	0.33	-0.73	0.45	-0.73	-0.73	-0.65	-0.58
Total Liab	-0.45	-0.73	-0.19	0.71	0.91		-0.71	-0.76	-0.73	-0.73	-0.45	0.31	-0.73	0.41	-0.74	-0.74	-0.66	-0.57
Total Current Assets	0.87	0.94	-0.52	-0.73	-0.76	-0.71		0.92	0.89	0.95	0.57	-0.05	0.9	-0.34	0.94	0.9	0.97	0.54
Common Stock	0.89	0.98	-0.4	-0.88	-0.76	-0.76	0.92		0.96	0.98	0.57	-0.38	0.99	-0.45	0.98	0.99	0.86	0.8
Net Tangible Assets	0.87	0.94	-0.39	-0.93	-0.73	-0.73	0.89	0.96		0.97	0.53	-0.43	0.97	-0.65	0.98	0.99	0.89	0.79
Accounts Payable	0.89	0.96	-0.45	-0.88	-0.75	-0.73	0.95	0.98	0.97		0.59	-0.3	0.98	-0.51	0.98	0.98	0.91	0.77
Property Plant Equipment	0.35	0.44	-0.29	-0.67	-0.77	-0.45	0.57	0.57	0.53	0.59		-0.43	0.55	-0.42	0.52	0.56	0.39	0.56
Current Deferred Revenue	-0.19	-0.25	-0.14	0.68	0.33	0.31	-0.05	-0.38	-0.43	-0.3	-0.43		-0.43	0.62	-0.32	-0.44	0.02	-0.75
Capital Surpluse	0.9	0.97	-0.41	-0.91	-0.73	-0.73	0.9	0.99	0.97	0.98	0.55	-0.43		-0.52	0.98	1.0	0.85	0.83
Deferred Long Term Liab	-0.31	-0.37	-0.05	0.79	0.45	0.41	-0.34	-0.45	-0.65	-0.51	-0.42	0.62	-0.52		-0.5	-0.57	-0.4	-0.67
Net Invested Capital	0.92	0.98	-0.47	-0.86	-0.73	-0.74	0.94	0.98	0.98	0.98	0.52	-0.32	0.98	-0.5		0.99	0.93	0.71
Capital Stock	0.9	0.97	-0.41	-0.92	-0.73	-0.74	0.9	0.99	0.99	0.98	0.56	-0.44	1.0	-0.57	0.99		0.87	0.82
Net Working Capital	0.87	0.91	-0.52	-0.68	-0.65	-0.66	0.97	0.86	0.89	0.91	0.39	0.02	0.85	-0.4	0.93	0.87		0.46
Short Term Debt	0.61	0.68	-0.11	-0.92	-0.58	-0.57	0.54	0.8	0.79	0.77	0.56	-0.75	0.83	-0.67	0.71	0.82	0.46

Click cells to compare fundamentals

About Nautilus Biotechnology Financial Statements

Nautilus Biotechnology shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Nautilus Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Nautilus Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nautilus Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Gross Profit	-5.7 M	-6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC